Biotech Stocks To Follow Now – April 24th
2025-04-26T06:04:59Z
Thermo Fisher Scientific, AbbVie, Danaher, Vertex Pharmaceuticals, and GSK are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies whose primary business is researching,…
Thermo Fisher Scientific, AbbVie, Danaher, Vertex Pharmaceuticals, and GSK are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies whose primary business is researching, developing, and commercializing products based on biological science—such as drugs, gene therapies, diagnostics, or agricultural innovations. Because their fortunes often hinge on the success of clinical trials and regulatory approvals, these stocks can offer substantial growth potential but also carry higher volatility and risk compared with more established sectors. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Get alerts:
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of NYSE:TMO traded down $10.51 on Thursday, hitting $421.13. The company had a trading volume of 1,490,659 shares, compared to its average volume of 1,729,073. Thermo Fisher Scientific has a 52-week low of $409.85 and a 52-week high of $627.88. The business has a 50 day moving average of $491.37 and a 200 day moving average of $530.03. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company has a market cap of $158.97 billion, a PE ratio of 25.50, a PEG ratio of 2.99 and a beta of 0.86.
Read Our Latest Research Report on TMO
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet’s diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn’s disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of NYSE:ABBV traded up $3.43 during trading on Thursday, reaching $180.48. 2,901,865 shares of the stock were exchanged, compared to its average volume of 6,013,689. The firm’s 50-day moving average price is $197.30 and its 200 day moving average price is $187.37. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66. AbbVie has a 12-month low of $153.58 and a 12-month high of $218.66. The firm has a market cap of $319.27 billion, a price-to-earnings ratio of 75.17, a price-to-earnings-growth ratio of 1.62 and a beta of 0.55.
Read Our Latest Research Report on ABBV
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Shares of DHR stock traded down $1.11 during mid-day trading on Thursday, reaching $195.20. 904,571 shares of the company were exchanged, compared to its average volume of 3,339,778. The company has a market capitalization of $139.51 billion, a P/E ratio of 36.93, a P/E/G ratio of 2.66 and a beta of 0.86. Danaher has a fifty-two week low of $171.00 and a fifty-two week high of $281.70. The business’s 50 day simple moving average is $201.21 and its 200 day simple moving average is $225.57. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.
Read Our Latest Research Report on DHR
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of Vertex Pharmaceuticals stock traded down $1.28 during trading hours on Thursday, reaching $491.14. The company’s stock had a trading volume of 277,622 shares, compared to its average volume of 1,325,326. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69. The company’s 50 day simple moving average is $488.48 and its 200 day simple moving average is $465.82. The stock has a market cap of $126.12 billion, a P/E ratio of -223.03, a price-to-earnings-growth ratio of 2.11 and a beta of 0.50. Vertex Pharmaceuticals has a one year low of $377.85 and a one year high of $519.88.
Read Our Latest Research Report on VRTX
GSK (GSK)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
GSK stock traded up $0.32 on Thursday, reaching $37.35. The company’s stock had a trading volume of 3,110,656 shares, compared to its average volume of 4,684,864. The company has a market capitalization of $77.07 billion, a P/E ratio of 23.49, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. GSK has a 52 week low of $31.72 and a 52 week high of $45.93. The firm has a fifty day moving average of $37.46 and a two-hundred day moving average of $36.06.
Read Our Latest Research Report on GSK
Read More
Auto-posted from news source
About The Author
